Last reviewed · How we verify
NCT04014764: (ANSWer)
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
trial testing This is a non-interventional study in Acute Myelogenous Leukemia in 119 participants. Completed in 31 March 2022.
31 March 2022
Quick facts
| Lead sponsor | Notable Labs |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 119 |
| Start date | 15 December 2019 |
| Primary completion | 31 March 2022 |
| Estimated completion | 31 March 2022 |
| Sites | 20 locations across United States, Greece, Spain |
Drugs / interventions tested
- This is a non-interventional study
Conditions studied
- Acute Myelogenous Leukemia — all drugs for Acute Myelogenous Leukemia →
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
- Lymphoma — all drugs for Lymphoma →
Sponsor
Notable Labs — full company profile →
Who can join
18 and older, any sex, with Acute Myelogenous Leukemia or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04014764
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of This is a non-interventional study
Trials testing the same drug.
- NCT05932043 — Development of the Work In Progress Questionnaire · unknown
- NCT04804566 — Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients · completed
- NCT05794217 — A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research · recruiting
- NCT06793254 — Translation, Cultural Adaptation and Validation of the Italian Version of Functional Rating Index in Patients With Chron · completed
- NCT05118217 — Microvascular Dysfunction in Diabetic Peripheral Neuropathy · unknown
Other recruiting trials for Acute Myelogenous Leukemia
Currently open trials in the same condition.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
- NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
- NCT06131801 — Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · recruiting
- NCT05974150 — Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04014764 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Notable Labs
- Last refreshed: 5 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04014764.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing